New leadership for Alexion ANZ

By Megan Brodie 2 years ago | In Comment, People
  • 2 years ago

28 September 2022

Alexion AstraZeneca Rare Disease has announced new leadership for its Australia and New Zealand affiliate following a decision by its current ANZ General Manager Sara Trafford-Jones to concentrate on building a Rare Disease Business Unit for the company in China.

Nicole Gaupset has been appointed to succeed Trafford-Jones in the role as General Manager, Australia and New Zealand, effective Saturday (1 October 2022).

“Nicole will replace Sara Trafford-Jones who will now fully dedicate herself to supporting AstraZeneca China to establish a new Rare Disease Business Unit,” a spokesperson for the company said.

“Sara is looking forward to finally realising our shared ambition to bring Alexion’s life transformative medicines to patients in China.”

“It’s been fantastic to work with Nicole and our leadership team over the past two years bringing access to our treatments in Australia whilst advocating for timely access to rare disease medicines in partnership with Medicines Australia, the Rare Industry Disease Working Group and Rare Voices Australia,” Trafford-Jones said.

“I am delighted to hand over the reins to such a seasoned and passionate leader.”

“This is an exciting time for Alexion AstraZeneca Rare Disease,” Gaupset said.

“We are focused on realising our vision of bringing our full portfolio of innovative medicines to people with rare diseases in Australia and New Zealand.

“I will continue the great work that Sara has been leading to ensure that people living with rare diseases in Australia and New Zealand are not left waiting for life-changing treatments that are readily available in other comparable countries.”

Trafford-Jones has been with Alexion for 14 years, joining it as Regional Marketing and Sales Director in 2008 and appointed ANZ GM in 2011. In 2015, she was appointed MD for Alexion in the UK, Ireland, Nordics and Baltics and followed by Vice President of Launch Excellence for Europe and Canada in 2018.

In September 2020, Trafford-Jones took on the South Cluster Lead executive leadership role, in charge of the Turkey, Brazil, Colombia businesses on top of her ANZ GM job and China. Appointed Vice President and International Shared Market Lead for China in July, the appointment of Gaupset now allows Trafford-Jones to concentrate her efforts on growing Alexion’s business in the Chinese market.

Gaupset is a highly qualified leader who brings a wide range of experiences and skills to the GM role. Prior to joining Alexion as Head of Commercial in January 2021, she was JPAC regional Head of External Affairs for Sanofi, based in Japan. Prior to that, she was Head of Market Access for Sanofi JPAC, also based in Japan.

Gaupset started her pharmaceutical career with Sanofi in Australia working in national sales and marketing roles for almost a decade before moving to Novartis in 2009, where she again had senior sales and marketing roles before moving to the commercial side of the business.

In 2014, she went to Novartis’ headquarters in Switzerland as Global Market Access Director for its cardiometabolic portfolio before being appointed Worldwide Patient Access Head for the area. She joined Sanofi JPAC in 2018.

©MedNews 2022

Leave a Reply